These were in part driven by specific genotype context, i.e. the CML cell line K562 was sensitive to BCR-ABL inhibitor dasatinib and the Src-family inhibitor saracatinib (Fig. 2A). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.